MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

B-cell malignancies

  • Home
  • B-cell malignancies
Structural Differences in Tisa-cel and Axi-cel CAR-T Therapies and Their Impact on CD19 Resistance in B-cell Malignancies
Posted inHematology-Oncology news Oncology

Structural Differences in Tisa-cel and Axi-cel CAR-T Therapies and Their Impact on CD19 Resistance in B-cell Malignancies

Posted by By MedXY 09/01/2026
Distinct CAR architectures in tisa-cel (4-1BB costimulation) and axi-cel (CD28 costimulation) influence mechanisms of resistance through CD19 loss, affecting relapse rates in B-cell malignancies treated with CD19-CAR-T therapies.
Read More
  • Evaluating the Impact of Early Mobilization in Mechanically Ventilated ICU Patients with Sepsis or Acute Respiratory Failure: Insights from the EVER Multicenter RCT
  • Evolving Trends in Pediatric Critical Care in the U.S. from 2001 to 2022: Implications for Healthcare Capacity and Regionalization
  • Understanding Acute Hypoxemic Respiratory Failure in ICU Patients: Epidemiology, Ventilatory Management, and Outcomes from a Multi-ICU Cohort Study
  • Long-Term Healthcare Utilization After COVID-19: Varied Patterns Based on Initial Infection Severity
  • Bridging the Gap: Ensuring Outpatient Follow-Up After Emergency Department Visits for Diabetes
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top